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Certain polymorphic variants of H-ras-1 and p53 have been investigated for an association
between inheritance and cancer risk. The results of a metaanalysis, which reviews studies of H-
ras-1 rare alleles and p53 codon 72 allelic variants in breast and lung cancer, are presented. The
data constituted evidence for elevated risk of both breast and lung cancer with inheritance of rare
H-ras-1 alleles. Calculated population attributable risks are 0.092 and 0.037 for breast and lung
cancer, respectively. The frequency of the rare H-ras-1 alleles was observed to be greater in
African Americans than in Caucasians, and a specific allele (A3.5) that is common in African
Americans was found only at low frequency in Caucasians. For p53 a consensus has yet to be
reached. Lung cancer studies conducted in Caucasian and African-American populations have
found no evidence of risk associated with the proline variant of codon 72. Two similar studies
conducted in Japanese populations suggested an association between p53 genotype distribution
and lung cancer risk. However, one implicates the proline allele but the other implicates the
arginine allele. The frequency of the proline variant is significantly dependent on race. Frequencies
have been reported for control populations of Japanese (0.347 and 0.401), Caucasian (0.295,
0.284, and 0.214), African American (0.628 and 0.527), and Mexican American (0.263). Environ
Health Perspect 105(Suppl 4):919-926 (1997)
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Introduction
Conserved nucleotide substitutions that
occur during evolution are considered to be
polymorphisms when the prevalence ofthe
rare or minor allele reaches 0.01 (1%) (1).
Repetitive DNA sequences are composed of
multiple consensus motifs. These consensus
motifs may be short (di- and trinucleotides)
or long (10-100 nucleotides) and are
arranged in tandem array. Concatenations
ofthese consensus motifs form minisatellite
or microsatellite regions that may be tens,
hundreds, or thousands of nucleotides in
length. Mutational pressures that lengthen
or shorten these reiterated sequences spawn
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multiallelic, variable (or hypervariable)
tandem repeat (VTR) polymorphisms (2).
These conserved DNA-polymorphisms may
be silent or they may encode a structural or
functional change.
Inheritance of mutations in certain
critical genes predispose to various types of
family cancer syndrome. These include
germ line mutations in p53, BRCA-1, Rb,
MCC, MSH-2, and WT-1 (3-12). The
identification, isolation, and cloning of
these genes has resulted in increased knowl-
edge of inheritance of these syndromes.
Overt predisposition to disease occurs when
a germ line mutation in a tumor suppressor
gene is inherited. Alternately, it is proposed
that more subtle predisposition to common
adult cancers may result from inheritance of
specific genetic polymorphisms. These may
alter susceptibility in conjunction with
certain environmental exposures.
To test this hypothesis several molecular
epidemiologic lung and breast cancer
case-control studies have been performed
(13-35). This report focuses on those
studies that have examined possible
associations between polymorphisms at the
H-ras-1 and p53 gene loci and lung cancer
and breast cancer predisposition.
The p53 gene is functionally character-
ized as a tumor suppressor gene (10).
Somatic mutations (primarily nucleotide
substitutions) of this gene have been
detected in diverse human cancer types
(36) and inheritance of germ line muta-
tions predispose to breast, colon, and brain
cancers (37,38). The role ofp53 is to pre-
vent tissue overgrowth; one mechanism
operates through abrogation of cells with
damaged genomes. Homeostatic control-
ling functions, even in the presence of
already severely damaged cells that are
being driven by activated protooncogenes
(oncogenes) may be maintained by a fully
functional p53 protein. The role ofp53 in
the life cycle of the cell is becoming
increasingly well understood. The p53 pro-
tein has been shown to have broad func-
tionality in cellular processes. These include
cell-cycle control, DNA repair, differentia-
tion, genomic plasticity, and apoptosis
(programmed cell death) (39-41).
Ten genetic polymorphisms that have
been described for p53 are cataloged in
Table 1 (21,42-53). Three of the five
nucleotide substitution polymorphisms are
silent, conferring no change in amino acid
sequence, and two cause amino acid sub-
stitutions. At codon 47 a proline to
serine substitution was found in 0 of 69
Caucasians and 3 of 32 (3 of 64 alleles,
0.047) African Americans; results ofin vitro
experiments that used a construct of this
allele containing a luciferase reporter gene
indicated that this polymorphism does not
interfere with growth-suppressor activity
(21). At codon 72 a G<-*C transition, rec-
ognized by Acc II and several isoschizomers
(Bsp50-1, BstUI, Bshl2361, MvnI, and
ThaI), accounts for an arginine*-+proline
amino acid substitution. The reported allelic
frequencies for this polymorphism are given
in Table 1 and vary with respect to race.
This polymorphism has been investigated in
several case-control studies oflung cancer,
as well as breast, colon, stomach, and blad-
der cancers (13-20). Five ofthe ten p53
polymorphisms occur in intronic sequences.
Three of these are revealed by restriction
digestion in introns 1, 6, and 7 (46,48,
49,51,54). One polymorphism is a six allele
VTR in intron 1 (55). In intron 3 there is a
biallelic 16 bp insertion/deletion (56). The
longer, minor allele (A2) is a direct repeat;
and though not independently confirmed
(57), it has been reported that women who
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Table 1. Polymorphisms in the p53tumor suppressor gene.
Location Characterization Frequencya Ethnicity References
Coding
Codon 21 GAC <-> GAT Ahuja et al. (45)
(Silent)
Codon 36 CCG <-> CCA 0.980 Felix et al. (52)
(Silent)
Codon 47 CCG *-> TCG 0.953 African American Felley-Bosco et al. (21)
(Pro <-4 Ser)
Codon 72 CGC <-> CCC 0.628,b0.527b African American Weston et al. (13,15); Jin etal. (18)
(Arg +4 Pro) 0.705,c0.786c Caucasian (United States/Europe) Weston etal. (13,15); To-Figueras et al. (20)
0.653,c0.599c Japanese Kawajiri et al. (14); Murata et al. (19)
0.737c Mexican American Jin et al. (18)
0.716c Swedish Birgander et al. (17)
0.830c Swedish Saamis Sj3lander et al. (54)
Codon 213 CGA -- CGG 0.968c United States Carbone etal. (53)
Noncoding
Intron 1 VTR, six alleles 0.02-0.46 Futrealetal. (47)
Intron 1 Hae IlIl restriction 0.770 Japanese Ito etal. (51)
Intron 3 16 bp insertion 0.875, 0.863 Caucasian (United States/Europe) Runnebaum etal. (56); Lancaster et al. (57)
Intron 6 Msp l/BstN1/Ncil 0.690 Caucasian Chumakov(48)
restriction (A - G) 0.856 Swedish Sjalander et al. (54)
0.740 United States McDaniel et al. (46)
Intron 7 Apal restriction 0.946 Caucasian Prosser and Condie (49)
(C<-T)
"Frequency of major allele. bProline. cArginine.
inherit thep53 repeated motif (A2) have an
excess riskofovarian cancer [odds ratio =8.6
(95% CI=3.0-25.2)] (58).
The H-ras-1 gene is a protooncogene
responsible for control ofcell growth (pro-
liferation) and specialization (differentia-
tion). Almost all protooncogenes encode a
protein component ofthe signal transduc-
tion cascade (59). This integrated multi-
process system is responsible for the
smooth, orderly, and specific transmission
of extracellular signals to the nucleus.
Activated ras genes predominate as the
family of oncogenes to be isolated from
solid tumors induced by chemicals in labo-
ratory animals. Members of the ras gene
family code for proteins of molecular
weight 21,000 (p21); these proteins are
membrane bound, have GTPase activity,
and form complexes with other proteins.
The ras genes are small G-proteins (gua-
nine nucleotide binding) that exert a pow-
erful proliferative response through signal
transduction (59).
Two VTR polymorphisms exist at the
H-ras-1 gene locus. Between the pseudo-
exon and exon 1 there is a short (12-24)
triallelic VTR composed of a 6 bp
consensus motif [(60); A. Weston et al.,
unpublished observations] (Figure 1).
Approximately 1.4 kb to the 3-prime end
ofthe structural gene there exists a longer
VTR. A 28 bp consensus sequence,
tandemly repeated between approximately
30 and 110 times, accounts for alleles that
are approximately 900 to 3000 bp in
length (61,62). More than 30 alleles have
been described and their frequencies have
been documented as common (0.07-0.65),
intermediate (0.005-0.015) and rare
(<0.005) (63). In 1985, Krontiris et al.
(61) reported that individuals who inher-
ited rare alleles were at increased risk of
cancer. In the intervening years, numerous
investigators have tried to replicate these
findings in specific cancer types through
case-control studies (22-35) and family
studies (32,33), with varying success.
This report is a metaanalysis that for-
mally summarizes the molecular epidemio-
logic data for the associations ofboth p53
and H-ras-1 polymorphisms with risk of
either breast cancer orlung cancer.
Methods
StudySubject
Subjects were either lung or breast cancer
cases and controls who participated in 21
reported studies (13-35). In the lung
cancer studies reported by Sugimura et al.
(24) and Weston et al. (25), subjects were




The H-ras-1 minisatellite VTR polymor-
phism has been determined by Southern
hybridization using an H-ras-1-derived
plasmid (pEQ and DNA fragment size
determination. Distinction of different





MspIlHpa II MspIlHpa II
24bp
Figure 1. Variable tandem repeat polymorphisms atthe H-ras-1 gene locus. The H-ras-1 gene is located on human
chromosome 11pl5.5. There are two VTR polymorphisms. Between the pseudo exon (0) and exon 1 there is a trial-
lelic 6 bp repeat motif that is reiterated two, three, or four times. The longest and shortest allelotypes are indi-
cated. Approximately 1.4 kb to the 3' end of the structural gene there is a multiallelic VTR consisting of a 28 bp
consensus sequence that is reiterated between 30 and 110times.
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restriction enzymes. These include
BamHI, Ava II, Taq I, Pvu II, Pst I, and
Msp IlHpa II. The restriction enzyme sites
that reside closest to the H-ras-1 VTR
region are MspIlHpaII. Digestion of
genomic DNA with MspIlHpaII and
Southern hybridization with pEC results
in fragments of approximately 0.9 to 3.0
kb. This indicates that Msp I (Msp I/
Hpa II) is the restriction enzyme ofchoice
for this analysis. Use of BamHI results in
H-ras-1 fragments ofapproximately 6.5 to
9.0 kb. Thus, it is more difficult to dis-
cern small differences using BamHI than
Msp I. Other enzyme choices have
intermediate sensitivity.
Recent improvements to specific allelic
identification have been made. Fifteen-cen-
timeter format agarose gels are elec-
trophoresed until the bromophenol blue
dye-front has migrated a distance ofat least
12 cm (24,34). Each gel includes samples
with known allelic composition verified
through blind analysis in different labora-
tories (24,34). Samples of similar migra-
tion characteristics are reanalyzed by
migration in adjacent lanes (24,25) or in
the same lane (34). Concatameric DNA
plasmids consisting of 30 to 50 bp incre-
ments (DNA ladders) are used for accurate
fragment size determination (26). Together
with the use of Msp IlHpa II, these
improvements yield highly consistent and
accurate determination ofH-ras-1 allotype.
Determination ofp53 Codon72
Polymorphism
The polymerase chain reaction and restric-
tion digestion ofpolymerase chain reaction
(PCR) amplicons are used to determine
this polymorphism. Using this basic strat-
egy, researchers have applied two methods.
First, a simple restriction digestion of an
amplified product has been used (14).
Alternately, a 3' mismatch primer incorpo-
rating a de novo Acc II restriction site has
been used to control for complete diges-
tion and concomitant allelic misclassi-
fication (13). In the latter method the




AGA3', and c) reverse 5'ACACCGGCGG
CCCCTGCACCA3'. Primers 1 and 2
were first used to generate a 397 bp tem-
plate. A heminested PCR using primers 1
and 3 was then used to generate fragments
for restriction analysis. Restriction enzymes
Acc II (US Biochemicals, Cleveland, OH;
no longer available; see "Introduction" for a
Table 2. H-ras-1 rare alleles and lung cancer.a
National origin of subject
(cases/controls) Relative risk (95% Cl) pValue Reference
United Kingdom (n=370/101) 1.2 (0.6-2.6) 0.590 Heighway et al. (22,23)
United States (n= 155/178) 1.9 (1.2-3.1) 0.006 Sugimura et al. (24,25)b
Norway (n= 118/123) 10.8 (1.4-85.4) 0.005 Ryberg et al. (26)
All (n= 643/402) 1.9 (1.3-2.8) 0.001 Combined analysisc
"Represents six independent studies from three independent laboratories. bDetection of racial variation in rare allele
frequency between African Americans and Caucasians in the United States. cTestfor homogeneity, p= 0.089.
Table 3. Evaluation ofthe p53codon 72 proline variant as a risk factorfor lung cancer.
National, ethnic origin Frequency of proline
of subjects (n) variant in controls pValuea Hardy-Weinbergb Reference
African American (95) 0.628 NS NS Weston et al. (13,15)
Caucasian (134) 0.295 NS NS Weston et al. (13,15)
Japanese (675) 0.347 0.33 (NS) 0.005 Kawajiri et al. (14)
Swedish (519) 0.284 NS NS Birgander et al. (17)
African American (141) 0.527 NSc NS Jin et al. (18)
Mexican American (82) 0.263 NSc NS Jin et al. (18)
Japanese (343) 0.401 NSd NSd Murata et al. (19)
Caucasian (286) 0.214 NS NS To-Figueras et al. (20)
NS, not significant. "Chi-square for difference in allelic frequencies between cancer cases and controls.
bGoodness of fit to the Hardy-Weinberg equilibrium for allelic distribution among lung cancer cases. cSignificant
in patients diagnosed before age 53 (p< 0.05, n= 44). dWhen analysis was performed independently for nonsmok-
ers, the genotypic distribution was significantly different between cases and controls (p = 0.009); the nonsmoking
case group was not in Hardy-Weinberg equilibrium (p= 0.018).
listing of isoschizomers) and Bsp50-I
(Stratagene, Lajolla, CA) were used to dis-
tinguish between the arginine (restriction
site present) and proline (restriction site
absent) alleles ofp53. Agarose gel electro-
phorsis (2%), with ethidium bromide detec-
tion, was used to separate the restriction
fragments and PCRproducts.
StatisticalAnalyses
To test whether the distribution of geno-
types was the same for cases and controls
within a given study, a chi-sqaure statistic
with 2 degrees offreedom was used (64).
Odds ratios from multiple studies were
combined to form a summary odds ratio
using the Mantel-Haenszel method (65).
For case-control studies ofp53 poly-
morphisms, the gene frequency for the
proline variant was estimated separately for
the cases and controls using the observed
number of individuals for each of three
genotypes (proline homozygotes, arginine
homozygotes, and heterozygotes). This
gene frequency in turn was used to calculate
the expected numbers ofindividuals for the
three genotypes in each group based on the
Hardy-Weinberg law ofequilibrium. To
test whether either the cases or the controls
were in equilibrium, a chi-square goodness
offit test was used (66). The Breslow-Day
test was used to assess homogeneity ofodds
ratios across various studies (67). Population
attributable risk (PAR) for inheritance of
H-ras-1 rare alleles in lung cancer and
breast cancer was determined according to
Kuritz and Landis (68). For H-ras-1, num-
bers ofsubjects in Tables 2 to 4 represent
numbers of individuals; however, chi-
square tests were performed on allelic
distributions and gene frequencies.
Results
LungCancerStudies
Inheritance ofH-ras-1 RareAlleles. Six
case-control studies in three laboratories
have examined the risk oflung cancer that
can be attributed to inheritance of rare H-
ras-1 alleles. Two ofthese studies were per-
formed in the United Kingdom and used
Pvu II for allele characterization (22,23).
Both studies used the same population-
based control group (n= 101). Although
both studies were positive [relative risks
(RRs) 1.4 and 1.1], neither study reached
statistical significance for risk of lung
cancer with inheritance of rare H-ras-1
alleles (combined analysis: RR= 1.2, 95%
CI =0.6-2.6, p=0.590, n=471; Table 2).
In the United States, Sugimura et al. (24)
and Weston et al. (25) performed three
independent studies oflung cancer risk and
inheritance of rare H-ras-1 alleles [also,
Weston et al., unpublished observations on
21 cases and 37 controls in an extension of
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Table 4. H-ras-1 rare alleles and breast cancer.
National origin of subjects
(cases/controls) Relative risk(95%CI) pValue Reference
Caucasian
(France, n= 104/56) 6.5(3.3-12.8) 0.000 Lidereau etal. (27)
Japanese
(n= 97/164) 2.6 (1.3-5.2) 0.007 Honda et al. (31)
Caucasian
(Italy, n= 92/60) 4.0(1.8-8.9) 0.000 Saglio et al. (30)
Caucasian
(Germany, n= 112/62) 1.3 (0.6-3.2) 0.498 Sheng et al. (29)
Caucasian
(Germany, n= 50/92) 1.8 (0.9-3.5) 0.075 Corell et al. (28)
Icelandic
(n= 56/48)a 1.2 (0.4-3.5) 0.798 Barkard6ttir et al. (32)
Caucasian
(United States, n= 23/50)b 2.9 (0.8-11.5) 0.109 Hall et al. (33)
United States
(n= 160/202) 2.0 (1.1-3.7) 0.028 Garrett etal. (34)c.d
United States
(n= 160/203) 3.0(1.5-6.1) 0.001
All (n= 694/937) 2.7 (2.1-3.4) 0.000 Combined analysis
Alle(n=590/881) 2.3 (1.7-2.9) 0.000 Combined analysisf
l,bNo evidence of linkage in 3 and 12 breast cancer families, respectively. cDetection of racial variation in rare
allele frequency between African Americans and Caucasians in the United States. dConway et al. (79) recently
reported confirmation of these findings using a PCR-based allotyping assay. "All subjects in table except France,
n=104/56 [Lidereau etal. (27)]. fTestfor homogeneity, p=0.477.
the study reported by Suguimura et al.
(24): the frequency ofrare alleles was 0.21
in cases and 0.05 in controls (chi-square=
8.4, p=0.02)]. All three were positive, and
each used Msp IlHpa II for allelic identifi-
cation. The combined RR estimate gener-
ated from these studies was 1.9 (95%
CI= 1.2-3.1, p=0.006, for 155 cases and
178 controls) (Table 2). A sixth indepen-
dent study ofsubjects in Norway was con-
ducted by Ryberg et al. (26). This study of
118 cases and 123 controls used Msp
I/Hpa II for allelic identification and found
a RRof 10.8 (95% CI = 1.4-85.4,p=0.005)
(Table 2). The combined summary statistic
for all lung cancer studies of H-ras-1 rare
allele inheritance indicates a RR of 1.9
(95% CI = 1.3-2.8, p=0.001, n=643/402;
test for homogeneity, p = 0.089). From
these data we calculated a lung cancer PAR
for inheritance of H-ras-1 rare alleles of
0.037 (3.7%) (68).
Inheritance ofPolymorphism in p53.
For p53 most studies have examined the
relationship between inheritance of the
codon 72 proline allelic variant and cancer
risk (Table 1). Seven studies are case-con-
trol investigations oflung cancer. In these
studies the allelic frequencies ofthe proline
variant do not differ between lung cancer
cases and controls (Table 3). However, the
proline variant was the major allele in
African Americans compared to Japanese,
Caucasians, and Mexican Americans where
the arginine allele was found to be most
prevalent (Tables 1, 3) (13-20). Among
Japanese, Kawajiri et al. (14) considered
allelic distribution as it pertained to the
Hardy-Weinberg equilibrium. Although
the arginine/proline allelic frequencies were
not different between cases and controls
(arginine allele 0.653 in controls, 0.645 in
cases), among controls the allelic distribu-
tion was in Hardy-Weinberg equilibrium
whereas in cases it was not. In cases there
was an underrepresentation ofheterozy-
gotes and an overrepresentation ofproline
homozygotes (p<0.005, Table 3). In
contrast, Murata et al. (19) examined the
relationship between the codon 72 poly-
morphism, lung cancer, and tobacco smok-
ing in a Japanese population but reported
an association ofp53 with tendency to
smoke tobacco, where the arginine allele
was elevated in nonsmoking cancer
patients (chi-square = 13.5, p<0.001). This
association was, in turn, the driving force
behind the subsequent observation that
arginine homozygotes were in excess
among nonsmoking lung cancer cases (chi-
square= 10.9, p<0.01) (19). Jin et al. (18)
detected elevated lung cancer risk associ-
ated with inheritance of the p53 proline
allele in a subset ofAfrican American lung
cancer cases diagnosed prior to the age of
53 years. Overall, however, Jin et al. found
no cancer risk associated with inheritance
ofthe p53 proline allele (18). To-Figueras
et al. (20) investigated this polymorphism
in relation to histologic type oflung cancer
in a Caucasian population in Catalonia. In
this population no association ofthep53,
codon 72, genotype was observed (20).
Birgander et al. (17) have extended
these p53 studies by considering inheri-
tance ofpairwise haplotypes ofthree poly-
morphicp53 loci. The loci ofinterest were
the codon 72 nucleic acid base substitu-
tion, the intron three 16 bp insertion
(A2)/deletion (Al), and the intron 6 Msp I
RFLP. Swedish Saamis were found to have
the highest frequency ofthe codon 72 argi-
nine variant so far described (0.830); evi-
dence from these studies did not support
the hypothesis that the codon 72 proline
variant is a risk factor for lung cancer. Nor
did the data suggest that the other p53
polymorphisms were independent lung-
cancer risk factors. However, the propor-
tion of proline/intron three Al to
proline/intron three A2 haplotypes was
found to be almost twice as frequent (1.78-
fold) in lung cancer cases as in controls
(p=0.032) (17). The data suggest that the
proline/intron three Al haplotype is a
lung-cancer risk factor. The same authors
have also shown that this haplotype may be
a riskfactor for colon cancer (16).
BreastCancerStudies
Inheritance ofH-ras-1 RareAlleles. For
breast cancer, nine studies have been
reported from eight laboratories between
1986 and 1993 (Table 4). All studies indi-
cate increased RR ofbreast cancer associ-
ated with inheritance of H-ras-l rare
alleles. The RRvalues ranged from 1.2 to
6.5; five studies were highly significant;
two studies were ofmarginal significance,
and two studies did not reach significance.
Overall there was a highly significant risk
ofbreast cancer associated with inheritance
of H-ras-1 rare alleles (RR= 2.7, 95%
CI=2.1-3.4, p=0.000, n= 1,631; Table 4;
(Figure 2). The Breslow-Day test for
homogeneity across these studies proved to
be almost significant (p=0.055); therefore,
the data were investigated further. Studies
on breast cancer used a range ofrestriction
enzymes for allelic classification (Figure 2,
legend). The enzyme likely to yield the
least accurate results, BamHI, was used in
the study that found the strongest associa-
tion between breast cancer risk and inheri-
tance ofrare H-ras-1 alleles (27). Although
the authors used Msp IlHpa II to confirm
rare alleles, when this study was omitted
from the analysis, the overall combined
data still yielded a statistically significant
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Figure 2. Relative risk of breast cancer associated
with inheritance of H-ras-1 rare alleles calculated for
nine published studies (1-7,9,10). Overall summary
statistic of these RR values was determined (8). Five
studies indicated a highly significant breast cancer risk
with inheritance of H-ras-1 rare alleles. These five
studies were reported as follows: Garrett et al. (34),
study 4, Honda et al. (31), study 5, and Garrett et al.
(34), study 7, used Msp 1. Saglio et al. (30), study 9,
used Ava II, and Lidereau et al. (27), study 10, used
BamHl. Two were of marginal significance: Corell et al.
(28), study 3, used Msp 1, and Hall et al. (33), study 6,
used Pst 1. Two studies did not reach significance:
Barkardottir et al. (32), study 1, used BamHll and Hirfl,
and Sheng et al. (29), study 2, used Msp 1. Overall a
highly significant breast cancer risk with inheritance of
H-ras-1 rare alleles was indicated (8, RR 2.7, 95%CI
2.1-3.4, p=0.000, n = 1631).
relative risk (RR= 2.3, 95% CI 1.7-2.9,
p=0.000, n= 1471; test for homogeneity,
p=0.477). The enzyme likely to yield the
most accurate allelic classification, Msp I,
was used in five studies. Analysis of the
data from only these studies found a
strong association between breast cancer
risk and H-ras-1 rare alleles (RR = 2.1,
95% CI 1.6-2.9, p= 0.000, n= 1142; test
for homogeneity, p=0.611). Based on all
of these studies a PAR for inheritance of
H-ras-1 in breast cancer was calculated to
be 0.092, or 9.2% (68).
Two studies examined inheritance of
rare alleles in families with a high inci-
dence of breast cancer. One study that
examined three Icelandic families found
no rare H-ras-1 alleles in any of 10 affected
members (32). In a second study, in the
United States, 12 breast cancer families
were studied (33). Seven of these twelve
families had members who carried rare
H-ras-1 alleles. However, no evidence was
found to support the hypotheses that
breast cancer cosegregated with either rare
or common H-ras-1 alleles (33).
Inheritance ofPolymorphism inp53.
Very limited data yet exist on the potential
association ofp53 polymorphisms and
breast cancer risk. A single study by
Kawajiri et al. (14) determined the allelic
frequencies ofthe p53 codon 72 polymor-
phism in breast cancer cases (n= 93) and
controls (n=347). The overall frequencies
for the proline variant were 0.328 for cases
and 0.347 for controls. These data do not
indicate that inheritance ofthis p53 poly-
morphism is a breast cancer risk factor.
Furthermore, Kawajiri et al. reported the
allelic distributions for cases and controls to
be similar (chi-square=3.18,p=0.2, degrees
offreedom=2), and both cases and control
populations were in Hardy-Weinberg
equilibrium (14).
Germ line mutations in the p53 gene
have a role in cancer family syndromes that
include breast cancer as a feature (38).
However, germ line mutations in p53 have
only been demonstrated in a small number
ofbreast cancers (69). In addition, germ line
p53 mutations have not been demonstrated
in pedigrees that have a specific family
historyofbreast orovarian cancer (70,71).
Discussion
InheritanceofH-ras-l RareAlleles
The data presented from molecular
epidemiologic case-control studies indicate
that inheritance ofH-ras-1 rare alleles con-
stitute lung cancer and breast cancer risk
factors. Every study discussed (six lung
cancer and nine breast cancer) indicated an
elevated RR ofeither lung or breast cancer.
Of the lung cancer studies, four of six
studies, coming from two ofthree indepen-
dent laboratories, were statistically signifi-
cant. Taken together, analysis ofall the data
pertaining to inheritance of H-ras-1 rare
alleles and lung cancer risk provided an
overall relative risk of 1.9 (95% CI 1.3-2.8,
p= 0.001). An even more convincing pic-
ture emerges for cancer ofthe breast. Nine
studies from eight independent laboratories
are reported. All were positive; five highly
significant, two approach significance
(p=0.075 and 0.109) and only two were
not significant. Taken together, analysis of
all ofthe data pertaining to inheritance of
H-ras-1 rare alleles and breast cancer risk
reveals a RR of 2.7 (95% CI 2.1-3.4,
p=0.000). The significance ofthese find-
ings is only diminished by the failure, so
far, to demonstrate linkage ofH-ras-1 rare
alleles with breast cancer in family studies.
However, these seemingly adverse observa-
tions may ultimately be resolved when a
mechanistic basis for cancer risk and H-ras-
1 rare alleles has been elucidated (see "Note
Added in Proof").
In breast cancer case-control studies,
based on the relative risk determinations
for inheritance of H-ras-1 rare alleles, the
data indicate a PAR of0.092 (9.2%). This
is consistent with the findings of Krontiris
et al. (35) that considered fewer studies.
The recently cloned BRCA-1 gene accounts
for PAR of only 0.046 (4.6%) (72). For
lung cancer the calculated PAR that we
determined was 0.037 (3.7%). These find-
ings indicate that inheritance of H-ras-I
rare alleles is an important risk factor for
both breast cancer and lung cancer.
Studies of cancer risk associated with
inheritance ofH-ras-1 rare alleles have pro-
vided data that are both positive and nega-
tive for multiple cancer types (35). Some
studies have clearly suffered from inade-
quate laboratory techniques leading to
inaccurate allelic classification; however,
controversial views have also stemmed
from the lack ofa plausible biologic mech-
anism to explain the potentially elevated
cancer risk associated with inheritance of
H-ras-1 rare alleles. Further laboratory
investigations, at the cell and molecular
level, of the association between inheri-
tance ofH-ras-1 rare alleles and increased
risk oflung cancer and breast cancer seem
justified from the molecular epidemiologic
data presented here.
There are several explanations for the
observation summarized that the inheri-
tance of H-ras-I rare alleles and cancer
risk are associated. First, the H-ras-I
VTR may be a marker that is simply in
linkage disequilibrium with another gene
that is responsible for cancer risk. Second,
evidence from loss-of-heterozygosity
studies has been provided that indicates
the presence ofa tumor suppressor gene at
chromosome lIp15.5 in both lung cancer
(73,74) and rhabdomyosarcoma (75).
Third, the specific rare allelomorphs of
H-ras-I may disrupt the controlled
expression of nearby genes, including
H-ras-I itself. This could operate through
transcriptional regulation. For example,
four members of the rel/NF-i'p gene fam-
ily oftranscription regulation factors bind
to the H-ras-1 minisatellite region (76).
Fourth, genetic recombinational events in
regions of the genome containing repeat
elements tend to be unstable; and fifth,
fidelity of DNA repair may be hampered
in regions containing tandem repeats (35).
InheritanceofPolymorphisms inp53
Since 1989 the importance ofmutations in
p53 has become central to human cancers.
Mutations in the p53 tumor suppressor
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gene have been recognized in many human
cancer types (77). Only recently has it been
questioned whether common polymor-
phisms in thep53 gene might have a role as
a cancer risk factor. At least 10 p53 poly-
morphisms have been identified to date
(Table 1). The codon 72 arginine/proline
polymorphism has been most extensively
studied, in part because it has a high preva-
lence. Convincing evidence that the codon
72 polymorphism has a role in cancer etiol-
ogy remains to be documented. Most
recently, haplotyping studies have suggested
that certain p53 polymorphisms may be a
marker for (that is, in linkage disequilib-
rium with) another chromosome 17p gene
responsible for disease risk (16,17).
Little evidence has been provided here
to implicate p53 polymorphisms in human
cancer risk (13-20). Other studies that
examined molecular mechanistic questions
using specific genetic constructs have also
failed to indicate disease risk (21). The
most recent studies that identify highly spe-
cific p53 haplotypes as cancer risk factors
require further investigation (16,17). These
investigations can usefully be pursued along
molecular epidemiological lines as well as
cell and molecular lines in the laboratory.
Although little evidence of breast and
lung cancer risk is evident from current
p53 polymorphism studies, reports exist to
implicate p53 polymorphisms in ovarian
cancer. A description has appeared in the
literature that implicates the intron 3,16 bp
insertion with risk of ovarian cancer
(RR= 8.6, 95% Cl 3.0-25.2) (57).
Conclusions
The published studies (22-34) that have
examined an association of inheritance of
the H-ras-I VTR with breast cancer are
remarkably consistent. All find a positive
association and most are statistically
significant (Figure 2). Fewer studies oflung
cancer point to a similar trend, indicating
inheritance of H-ras-1 rare alleles to be a
significant risk factor.
Studies of polymorphisms in p53 are
currently less well developed (13-21).
Most have focused on the codon 72
polymorphism, for which the weight of
evidence appears to support the null hypo-
thesis. However, considerable possibilities
exist given the pivotal role of this gene in
neoplasia and the number of polymor-
phisms so far reported (21,42-53). Recent
studies have led to consideration of
estimated haplotypes (16,17). New direc-
tions in our laboratory have focused on the
absolute determination of haplotypes in
diploid genomes using available molecular
biologic technologies (78).
NOTE ADDED IN PROOF: For H-ras-1
an interaction between rare alleles and
mutated BRCA-1 has been reported (80).
In addition, two reports have been pub-
lished that indicate a specific p53 haplo-
type, consisting of a constellation of 3
polymorphisms (intron 3, exon 4, and
intron 6) and designated 1-2-1, is a breast
cancer risk factor (78,81).
REFERENCES
1. Congress of the United States and Office of Technology.
Mapping Our Genes. Genomic Projects: How Big, How Fast?
Baltimore, MD:Johns Hopkins University Press, 1988.
2. Nakamura Y, Leppert M, O'Connell P, Wolff R, Holm T,
Culver M, Martin C, Fujimoto E, Hoff M, Kumlin E et al.
Variable number oftandem repeat (VNTR) markers for human
gene mapping. Science 235:1616-1622 (1987).
3. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC,
Jessup JM, van Tuinen P, Ledbetter DH, Barker DF,
Nakamura Y. Chromosome 17 deletions and p53 gene muta-
tions in colorectal carcinomas. Science 244:217 (1989).
4. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout
R, Gallie BL, Murphree AL, Strong LC, White RL. Expression
of recessive alleles by chromosomal mechanisms in retinoblas-
toma. Nature 305:779 (1983).
5. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert
JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW et
al. Identification of a chromosome 18q gene that is altered in
colorectal cancers. Science 247:49 (1990).
6. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB,
Kelly JS, Pressinger, AC, Hamilton SR, Hedge P, Markham A
et al. Identification ofa gene located at chromosome 5q21 that
is mutated in colorectal cancers. Science 251:1366 (1991).
7. Koufos A, Hansen MF, Lampkin BC, Workman ML,
Copeland NG, Jenkins NA, Cavenee WK. Loss ofalleles at loci
on human chromosome 11 during genesis ofWilms' tumour.
Nature 309:170 (1984).
8. Olschwang S, Laurent-Puig P, White GR, Thomas G. Germ
line mutations in the first 14 exons ofthe adenomatous polypo-
sis coligene. AmJ Hum Genet 52:273 (1993).
9. Spiro L, Olschwang S, Groden J, Robertson M, Samowitz W,
Joslyn G, Gelbert L, Thliveris A, Carlson M. Alleles of the
APC gene: an attenuated form of familial polyposis. Cell
75:951 (1993).
10. Weinberg RA. Tumor suppressor genes. Science 254:1138
(1991).
11. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman
K, Tavtigian S. A strong candidate for the breast and ovarian
cancer susceptibility gene BRCA-1. Science 266:66-71 (1994).
12 Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K,
Garber JE. Mutations in the BRCA-J gene in families with
early-onset breast and ovarian cancer. Nat Genet 8:387-91
(1994).
13. Weston A, Perrin LS, Forrester K, Hoover RN, Trump BF,
Harris CC, Caporaso NE. Allelic frequency of a p53 polymor-
phism in human lung cancer. Cancer Epidemiol Biomarkers
Prev 1:481-483 (1992).
14. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi SI. Germ
line polymorphisms ofp53 and CYPIA] genes involved in
human lung cancer. Carcinogenesis 14:1085-1089 (1993).
15. Weston A, Ling-Cawley HM, Caporaso NE, Bowman ED,
Hoover RN, Trump BF, Harris CC. Determination of the
allelic frequencies of an L-myc and a p53 polymorphism in
human lung cancer. Carcinogenesis 15:583-587 (1994).
16. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J,
Beckman L, Beckman G. p53 Germ line haplotypes associated
with increased risk for colorectal cancer. Carcinogenesis
16:1461-1464 (1995).
17. Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg
MI, Seidegard J, Tornling G, Beckman G, Beckman L. p53
Polymorphisms and haplotypes in lung cancer. Carcinogenesis
16:2233-2236 (1995).
18. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn
SE, Spitz MR. Higher lung cancer risk for younger African-
Americans with the Pro/Pro p53 genotype. Carcinogenesis
16:2205-2208 (1995).
19. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S,
Saisho H. Ana[ysis of a germ line polymorphism of the p53
gene in lung cancer patients; discrete results with smoking his-
tory. Carcinogenesis 17:261-264 (1996).
20. To-Figueras J, Gene M, Gomez-Catalan, Firvida J, Fuentes M,
Rodamilans M, Huguet E, Estape J, Corbella J. Glutathione
924 Environmental Health Perspectives * Vol 105, Supplement 4 * June 1997POLYMORPHISMS AND DISEASE SUSCEPTIBILTY
S-transferase MI and codon 72 p53 polymorphisms in a north-
western Mediterranean population and their relation to lung
cancer susceptibility. Cancer Epidemiol Biomarkers Prev
5:337-342 (1996).
21. Felley-Bosco E, Weston A, Cawley HM, Bennet WP, Harris
CC. Functional studies ofa germ-line polymorphism at codon
47 within thep53gene. AmJ Hum Genet 53:752-759 (1993).
22. Heighway J, Thatcher N, Cerny T, Hasleton PS. Genetic pre-
disposition to human lung cancer. Br J Cancer 53:453-457
(1986).
23. White GRM, Santibanez-KorefM, HeighwayJ. Constitutional
frequencies ofc-Ha-rasalleles in patients with different types of
lung cancer. BrJ Cancer 61:186 (1990)
24. Sugimura H, Caporaso NE, Hoover RN, Modali R, Resau J,
Trump BF, Lonergan JA, Krontiris TG, Mann DL, Weston A
et al. Association of rare alleles of the Harvey-ras protoonco-
gene locus with lung cancer. Cancer Res 50:1857 (1990).
25. Weston A, Vineis P, Caporaso NE, Krontiris TG, Lonergan JA,
Sugimura H. Racial variation in the distribution of Ha-ras-1
alleles. Mol Carcinog 4:265-268 (1991).
26. Ryberg D, Tefre T, Ovrebo S, Skaug V, Stangeland L,
Naalsund A, Baera R, Borresen AL, Haugen A. Ha-ras-1 alleles
in Norwegian lung cancer patients. Hum Genet 86:40-44
(1990).
27. Lidereau R, Escot C, Theillet C, Champeme MH. Brunet M,
GestJ, Callahan R. High frequency ofrare alleles ofthe human
c-Ha-ras-1 proto-oncogene in breast cancer patients. J Natl
Cancer Inst 77:697-701 (1986).
28. Corell B, Zoll B. Comparison between the allelic frequency dis-
tribution of the Ha-ras 1 locus in normal individuals and
patients with lymphoma, breast, and ovarian cancer. Hum
Genet 79:255-259 (1988).
29. Sheng ZM, Guerin M, Gabillot M, Speielmann M, Riou G.
c-Ha-ras-1 polymorphism in human breast carcinomas: evi-
dence for a normal distribution of alleles. Oncogene Res
2:245-250 (1988).
30. Saglio G, Camaschella C, Giai M, Serra A, Guerrasio A,
Peirone B, Gasparini P, Mazza U, Ceppellini R, Biglia N et al.
Distribution ofHa-ras-I proto-oncogene alleles in breast cancer
patients and in a control population. Breast Cancer Res Treat
11:147-153 (1988).
31. Honda K, Ishizaki K, Ikenaga M, Toguchida J, Inamoto T,
Tanaka K, Ozawa K. Increased frequency ofspecific alleles of
the c-Ha-ras gene in Japanese cancer patients. Hum Genet
79:297-300 (1988).
32. Barkard6ttir RB, J6hannsson OT, Arason A, Gundnason V,
Egilsson V. Polymorphism ofthe c-Ha-ras-1 proto-oncogene in
sporadic and familial breast cancer. Int J Cancer 44:251-255
(1989).
33. Hall JM, Huey B, Morrow J, Newman B, Lee M, Jones E,
Carter C, Buehring GC, King MC. Rare H-ras alleles and sus-
ceptibility to human breast cancer. Genomics 6:188-191
(1990).
34. Garrett PA, Hulka BS, Kim YL, Farber RA. H-ras protoonco-
gene polymorphism and breast cancer. Cancer Epidemiol
Biomarkers Prev 2:131-138 (1993).
35. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An
association between the risk ofcancer and mutations in the H-
ras-1 minisatellite locus. N EnglJ Med 329:517-523 (1993).
36. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R,
Cleary K, Bigner, SH, Davi son N, Baylin S, Devilee P et al.
Mutations in the p53 gene occur in diverse human tumor
types. Nature 342:705 (1989).
37. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL,
Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB,
Sasaki MS et al. Prevalence and spectrum ofgerm line muta-
tions ofthe p53 gene among patients with sarcoma. N Engl J
Med 326:1301-1308 (1992)
38. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH,
Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J et
al. Germline mutations of the p53 tumor-suppressor gene in
children and young adults with second malignant neoplasms.
NEnglJ Med 326:1309-1315 (1992).
39. Harris CC. p53: at the crossroads ofmolecular carcinogenesis
and cancer risk assessment. Science 262:1980-1981 (1993).
40. Fields S, Jang SK. Presence ofa potent transcription activating
sequence in the p53 protein. Science 249:1046-1048 (1990).
41. Chen PL, Chen Y, Bookstein R, Lee WH. Genetic mechanisms
of tumor suppression by the human p53 gene. Science
250:1576-1580 (1991).
42. De la Calle-Martin 0, Fabregat V, Romero M, Soer J, Vives J,
Yague J. AccII polymorphism ofthe p53 gene. Nucleic Acids
Res 18:4963 (1990).
43. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism
ofthe TP53 gene. NucleicAcids Res 18:4961 (1990).
44. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J,
Crawford LV. Primary structure polymorphism at amino acid
residue 72 ofhumanp53. Mol Cell Biol 7:961-963 (1987).
45. Ahuja HG, Testa MP, Cline MJ. Variation in the protein cod-
ing region of the human p53 gene. Oncogene 5:1409-1410
(1990).
46. McDaniel T, Carbone D, Takahashi T, Chumakov P, Chang
EH, Pirollo KF, Yin J, Huang Y, Melzer SJ. The Msp I poly-
morphism in intron 6 ofp53 (TP53) detected by digestion of
PCRproducts. NucleicAcids Res 19:4796 (1991).
47. Futreal PA, Barrett JC, Wiseman RW. An alu polymorphism
intragenic to the TP53gene. NucleicAcids Res 19:6977 (1991).
48. Chumakov PM. Jenkins JR. BstNIINcil polymorphism of the
humanp53gene (TP53). NucleicAcids Res 19:6969 (1991).
49. ProsserJ, Condie A. Biallelic apal polymorphism ofthe human
p53 gene (TP53). NucleicAcids Res 19:4799 (1991).
50. Lazar V, Hazard F, Bertin F, Janin N, Belllet D, Bressac B.
Simple sequence repeat polymorphism within the p53 gene.
Oncogene 8:1703-1705 (1993).
51. Ito T, Seyama T, Hayashi T, Mizuno T, Iwamoto KS,
Tsuyama N, Dohi K, Nakamura N. HaeIII polymorphism in
intron 1 ofthe humanp53gene. Hum Genet 93:222 (1994).
52. Felix CA, Brown DL, Mitsudomi T, Ikagaki N, Wong A,
Wasserman R, Womer RB, Biegel JA. Polymorphism at codon
36 ofthep53gene. Oncogene 9:327-328 (1994).
53. Carbone D, Chiba I, Mitsudomi T. Polymorphism at codon
213 within thep53 gene. Oncogene 6:1691-1692 (1991).
54. Sjalander A, Birgander R, Kivela A, Beckman G. p53
Polymorphisms and haplotypes in different ethnic groups.
Hum Hered 45:144-149 (1995).
55. Hahn M, Serth J, Fislage R, Wolfes H, Allhoff E, Jonas U,
Pingoud A. Polymerase chain reaction detection of a highly
polymorphic VNTR segment in intron 1 of the human p53
gene. Clin Chem 39:549-550 (1993).
56. Runnebaum IB, Tong XW, Moebus V, Heilmann V, Kieback
DG, Kreienberg R. Multiplex PCR screening detects small p53
deletions and insertions in human ovarian cancer cell lines.
Hum Genet 83:620-624 (1994).
57. Lancaster JM, Brownlee HA, Wiseman RW, Taylor J. p53
Polymorphism in ovarian and bladder cancer. Lancet 346:8968
(1995).
58. Runnebaum IB, Tong XW, Konig R, Hong Z, Korner K,
Atkinson EN, Kreienberg R, Keiback DG. p53-Based blood
test for p53PIN3 and risk for sporadic ovarian cancer. Lancet
345:994 (1994).
59. Krontiris TG. Oncogenes. N EnglJ Med 333:303 (1995).
60. Iwahana H. Orita M, Kanazawa H, Hayashi K, Sekiya T. A
new RFLP in intron 1 ofthe human c-Ha-ras-1 gene and its
close relationship with the variable tandem repeats in the region
3' to the gene. Oncogene 5:1049-1053 (1990).
61. Krontiris TG, DiMartino NA, Colb M, Parkinson DR.
Unique allelic restriction fragments ofthe human Ha-ras locus
in leukocyte and tumour DNAs of cancer patients. Nature
313:369-374 (1985).
62. Feinberg AP, Vogelstein B. Hypomethylation of ras oncogenes
in primary human cancers. Biochem Biophys Res Commun
111:47-54 (1983).
Environmental Health Perspectives * Vol 105, Supplement 4 * June 1997 925WESTON AND GODBOLD
63. Krontiris TG, DiMartino NA, Colb M, Mitcheson HD,
Parkinson DR. Human restriction fragment length polymor-
phisms and cancer risk assessment. J Cell Biochem 30:319-329
(1986).
64. Altman DG. Practical Statistics for Medical Research. New
York:Chapman and Hall, 1991;259-264.
65. Mantel N, Haenszel W. Statistical aspects of the analysis of
data from retrospective studies of disease. J Natl Cancer Inst
22:719-748 (1959).
66. Li CC. Human Genetics. NewYork:McGraw-Hill, 1961;15-27.
67. Breslow NE, Day NE. The analysis ofcase-control studies. In:
Statistical Methods in Cancer Research, Vol 1 (Bjelke E,
Breslow NE, Cole P, Haenszel W, Hill C, Howe G, Miller AB,
Modan B, Modan M, Pike M et al., eds). IARC Scientific
Publications No 32. Lyon:International Agency for Research
on Cancer, 1980;182.
68. Kuritz SJ, Landis JR. Summary attributable risk estimation from
unmatched case-control data. Stat in Med 7:507-517 (1988).
69. Prosser J, Thompson AM, Cranston G, Evans HJ. Evidence
thatp53 behaves as a tumour suppressor gene in sporadic breast
tumours. Oncogene 5:1573-1579 (1990).
70. Prosser J, Elder PA, Condie A, MacFadyen I, Steel CM, Evans
HJ. Mutations in p53 do not account for heritable breast
cancer: a study in five affected families. Br J Cancer
63:181-184 (1991).
71. Warren W, Eeles RA, Ponder BAJ, Easton DF, Averill D,
Ponder MA. No evidence for germline mutations in exons 5-9
of the p53 gene in 25 breast cancer families. Oncogene
7:1043-1046 (1992).
72. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA,
Huey B, King MC. Linkage ofearly-onset familial breast cancer
to chromosome 17q2l. Science 250:1684-1689 (1990).
73. Weston A, WilleyJC, Modali R, Sugimura H, McDowell EM,
Resau J, Light B, Haugen A, Mann DL, Trump BF et al.
Differential DNA sequence deletions from chromosomes 3, 11,
13 and 17 in squamous cell carcinoma, large cell carcinoma and
adenocarcinoma of the human lung. Proc Natl Acad Sci USA
86:5099 (1989).
74. Ludwig CU, Raefle G, Dalquen P, Stulz P, Stahel R, Obrecht
JP. Allelic loss on the short arm of chromosome 11 in non-
small-cell lung cancer. IntJ Cancer 49:661-665 (1991).
75. Scrable HJ, Witte DP, Lampkin BC, Casvenee WK.
Chromosomal localization of the human rhabdomyosarcomas
locus by mitotic recombination mapping. Nature 329:645-647
(1987).
76. Trepicchio WL, Krontiris TG. Members oftherel/NF-Kp family
oftranscriptional regulatory factors bind the H-ras-I minisatellite
DNAsequence. NucleicAcids Res 20:2427-2434 (1992).
77. Greenb att MS, Bennett WP, Hollstein M, Harris CC.
Mutations in the p53 tumor suppressor gene: clues to cancer eti-
ology and molecular pathogenesis. Cancer Res 54:4855 (1994).
78. Weston A, Pan C-F, Ksieski HB, Wallenstein S, Berkowitz GS,
Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff, MS. p53
Haplotype determination in breast cancer. Submitted to
Cancer Epidemiol Biomarkers Prev 6:105-112 (1997).
79. Conway K, Edmiston SN, Hulka BS, Garrett PA, Liu ET.
Allele length and minisatellite variant repeat analyses ofthe Ha-
ras VNTR in a breast cancer case-control study. Proc Am
Assoc Cancer Res 37:A1764 (1996).
80. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Rutledge
MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF,
Ponder BA et al. Ovarian cancer risk in BRCA1 carriers is mod-
ified by HRAS1 variable number of tandem repeat (VNTR)
locus. Nat Genet 12:309-311 (1996).
81. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P,
Athlin L, Beckman G, Beckman L. p53 polymorphisms and
haplotypes in breast cancer. Carcinogenesis 17:1313-1316
(1996).
926 Environmental Health Perspectives * Vol 105, Supplement 4 * June 1997